Commercial Assessment of the Diabetic Nephropathy Market 2026-2036 Featuring Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, UCB Biopharma, Serodus, and Palatin
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Diabetic Nephropathy - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The diabetic nephropathy and diabetes kidney disease (DKD) market reached approximately USD 8.80 billion in 2025 across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Supported by increasing disease prevalence, earlier intervention, broader adoption of targeted therapies, and continued pharmaceutical innovation, the market is expected to expand at a compound annual growth rate of approximately 5% from 2026 to 2036.
The report providesan in-depth assessment of historical and forecast epidemiology, treatment practices, market size, therapy uptake, pricing trends, competitive positioning, and unmet medical needs across the 7MM.
Key Diabetic Nephropathy and Diabetes Kidney Disease Market Findings
The concentration of DKD among older adults reflects its association with long-standing diabetes and progressive renal impairment. This trend reinforces the importance of annual renal function and albuminuria assessments, timely diagnosis, sustained glycemic and blood pressure management, and earlier use of therapies with demonstrated kidney and cardiovascular benefits.
DKD Treatment Landscape Continues to Evolve
Current diabetic kidney disease management follows an individualized, stepwise approach designed to preserve renal function, slow disease progression, and reduce cardiovascular morbidity and mortality. Treatment strategies include lifestyle management, glycemic control, blood pressure and lipid management, renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and other glucose-lowering therapies selected according to renal function and comorbidities.
SGLT2 inhibitors, including empagliflozin (JARDIANCE) and dapagliflozin (FARXIGA/FORXIGA), have contributed to a significant shift in clinical practice because of evidence supporting renal and cardiovascular protection. Finerenone (KERENDIA), a non-steroidal mineralocorticoid receptor antagonist, has further expanded the treatment landscape by targeting pathways associated with inflammation and fibrosis.
Leading companies in the marketed DKD therapeutics landscape include Boehringer Ingelheim and Eli Lilly with JARDIANCE, Bayer with KERENDIA, and AstraZeneca with FARXIGA/FORXIGA. The competitive environment also includes UCB Biopharma, Daiichi Sankyo, Serodus, Palatin Technologies, Novo Nordisk, and Inversago Pharma, among others.
In March 2026, a Phase III study of KERENDIA reported that the therapy met its primary endpoint in patients with chronic kidney disease, demonstrating a statistically significant improvement in the estimated glomerular filtration rate slope compared with placebo. The reported safety profile was consistent with previous findings.
Emerging DKD Pipeline Supports Future Market Growth
The diabetic nephropathy and diabetes kidney disease pipeline includes therapies targeting distinct metabolic, hemodynamic, inflammatory, and fibrotic pathways. Notable candidates include esaxerenone (MINNEBRO) from Daiichi Sankyo, SER150 from Serodus, bremelanotide (VYLEESI) from Palatin Technologies, and INV-202 from Novo Nordisk and Inversago Pharma.
These candidates are being evaluated across different stages of renal impairment, reflecting increased industry focus on stage-specific treatment and prevention of disease progression. Uptake of emerging therapies is expected to depend on clinical efficacy, safety, administration requirements, regulatory outcomes, reimbursement, guideline inclusion, and differentiation from established standards of care.
Recently introduced targeted therapies are anticipated to achieve moderate to high uptake as physician confidence in early cardio-renal intervention increases. Pipeline products may experience more gradual adoption while confirmatory clinical data, real-world evidence, and market access frameworks continue to develop.
Persistent Unmet Needs Create Strategic Opportunities
Despite advances in treatment, the DKD market continues to face major clinical and commercial challenges. Priority unmet needs include:
These gaps create opportunities for developers advancing differentiated therapies that can improve renal outcomes, reduce cardiovascular events, demonstrate favorable safety, and support convenient long-term disease management.
Comprehensive DKD Market Intelligence and Competitive Analysis
The report evaluates the diabetic kidney disease market from 2022 through 2036, including patient population forecasts, therapy-specific revenue, market share, drug adoption, peak patient share, pricing, analogue assessment, and geographic growth opportunities. Drug profiles review mechanisms of action, clinical trial findings, regulatory milestones, patents, collaborations, strategic partnerships, advantages, limitations, and recent developments.
The analysis also incorporates insights from key opinion leaders and subject-matter experts across the 7MM. Research engagement included specialists associated with institutions such as the University of North Carolina at Chapel Hill, the Berlin Institute of Health at Charite, and the University of Nottingham. Expert perspectives were used to assess evolving treatment practices, prescribing patterns, patient adherence, therapy switching, market access barriers, pipeline prioritization, and epidemiological trends.
Qualitative assessment includes SWOT and conjoint analyses covering efficacy, safety, route and frequency of administration, order of market entry, probability of success, cost-effectiveness, geographic accessibility, and addressable patient populations. These findings support pharmaceutical companies, investors, healthcare organizations, and other stakeholders in evaluating DKD market attractiveness and developing evidence-based clinical, commercial, and market access strategies.
Report Coverage
Rising prevalence, the transition toward targeted cardio-renal therapies, and continued pipeline development are expected to sustain growth in the diabetic nephropathy and diabetes kidney disease market through 2036. Companies capable of addressing early diagnosis, renal preservation, cardiovascular risk, treatment accessibility, and long-term adherence will be well positioned to capture emerging opportunities across the 7MM.
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/f6hia
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.